Harmony Biosciences Holdings, Inc. Common Stock HRMY
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:47:43.791Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:26:53.807733875Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T02:47:43.399119+00:00
Harmony Biosciences Holdings, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 47.16 | 205.3% | 40.8% | |||
| 25Δ | ||||||
| 30Δ | 38.05 | 108.2% | 14.0% | 32.63 | 67.0% | 6.9% |
| 35Δ | 36.86 | 96.8% | 10.9% | 33.12 | 69.0% | 6.3% |
| 40Δ | 36.03 | 90.2% | 8.8% | 33.60 | 71.1% | 5.6% |
| 45Δ | 35.19 | 83.7% | 6.8% | 34.09 | 73.1% | 5.0% |
| 50Δ | 34.69 | 77.9% | 5.7% | 34.57 | 75.2% | 4.4% |
| 55Δ | 34.29 | 72.4% | 4.9% | 35.07 | 76.9% | 3.7% |
| 60Δ | 33.89 | 66.8% | 4.0% | 35.66 | 76.8% | 3.2% |
| 65Δ | 33.50 | 61.3% | 3.2% | 36.26 | 76.6% | 2.7% |
| 70Δ | 33.10 | 55.7% | 2.4% | 36.85 | 76.4% | 2.1% |
| 75Δ | 32.70 | 50.1% | 1.5% | 37.44 | 76.2% | 1.6% |
| 80Δ | 32.18 | 47.1% | 1.0% | 39.26 | 92.4% | 1.4% |
20Δ
- Pseudo strike
- 47.16
- IV
- 205.3%
- B/E move
- 40.8%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 38.05
- IV
- 108.2%
- B/E move
- 14.0%
- Pseudo strike
- 32.63
- IV
- 67.0%
- B/E move
- 6.9%
35Δ
- Pseudo strike
- 36.86
- IV
- 96.8%
- B/E move
- 10.9%
- Pseudo strike
- 33.12
- IV
- 69.0%
- B/E move
- 6.3%
40Δ
- Pseudo strike
- 36.03
- IV
- 90.2%
- B/E move
- 8.8%
- Pseudo strike
- 33.60
- IV
- 71.1%
- B/E move
- 5.6%
45Δ
- Pseudo strike
- 35.19
- IV
- 83.7%
- B/E move
- 6.8%
- Pseudo strike
- 34.09
- IV
- 73.1%
- B/E move
- 5.0%
50Δ
- Pseudo strike
- 34.69
- IV
- 77.9%
- B/E move
- 5.7%
- Pseudo strike
- 34.57
- IV
- 75.2%
- B/E move
- 4.4%
55Δ
- Pseudo strike
- 34.29
- IV
- 72.4%
- B/E move
- 4.9%
- Pseudo strike
- 35.07
- IV
- 76.9%
- B/E move
- 3.7%
60Δ
- Pseudo strike
- 33.89
- IV
- 66.8%
- B/E move
- 4.0%
- Pseudo strike
- 35.66
- IV
- 76.8%
- B/E move
- 3.2%
65Δ
- Pseudo strike
- 33.50
- IV
- 61.3%
- B/E move
- 3.2%
- Pseudo strike
- 36.26
- IV
- 76.6%
- B/E move
- 2.7%
70Δ
- Pseudo strike
- 33.10
- IV
- 55.7%
- B/E move
- 2.4%
- Pseudo strike
- 36.85
- IV
- 76.4%
- B/E move
- 2.1%
75Δ
- Pseudo strike
- 32.70
- IV
- 50.1%
- B/E move
- 1.5%
- Pseudo strike
- 37.44
- IV
- 76.2%
- B/E move
- 1.6%
80Δ
- Pseudo strike
- 32.18
- IV
- 47.1%
- B/E move
- 1.0%
- Pseudo strike
- 39.26
- IV
- 92.4%
- B/E move
- 1.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 68.30% | |
| 67.46% | |
| 78.41% | |
| 81.79% | |
| 82.10% | |
| 49.84% | |
| 44.44% | |
| 45.29% | |
| 48.21% | |
| 51.20% | |
| 50.44% | |
| 50.25% | |
| 49.97% | |
| 52.98% | |
| 52.59% | |
| 51.91% | |
| 59.40% | |
| 58.17% | |
| 59.83% | |
| 55.95% | |
| 58.92% | |
| 73.67% | |
| 56.17% | |
| 53.42% | |
| 59.65% | |
| 57.39% | |
| 59.61% | |
| 60.23% | |
| 64.43% | |
| 63.65% | |
| 59.41% | |
| 61.97% | |
| 63.05% | |
| 62.96% | |
| 70.04% | |
| 72.21% | |
| 71.52% | |
| 69.87% | |
| 83.33% | |
| 72.85% | |
| 77.11% | |
| 98.07% | |
| 70.30% | |
| 70.38% | |
| 69.00% | |
| 65.13% | |
| 77.06% | |
| 71.59% | |
| 73.42% | |
| 61.85% | |
| 65.45% | |
| 64.31% | |
| 67.61% |
Biotechnology
HUMA
Humacyte Inc (HUMA) is a groundbreaking biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels…
More →IBRX
Description unavailable
More →IDYA
IDEAYA Biosciences, Inc., a synthetic precision medicine oncology company focused on lethality, is focused on the discovery and development of targeted therapies for selected…
More →IFRX
InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company is…
More →IGC
India Globalization Capital, Inc. buys and resells physical infrastructure commodities. The company is headquartered in Potomac, Maryland.
More →IMCR
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is…
More →